{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:12:08Z","timestamp":1788455528889,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N01796X\/1"],"award-info":[{"award-number":["MR\/N01796X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science","award":["2018-I2M-2-002"],"award-info":[{"award-number":["2018-I2M-2-002"]}]},{"name":"Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science","award":["2018-I2M-2-002"],"award-info":[{"award-number":["2018-I2M-2-002"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["197785619\/SFB1021"],"award-info":[{"award-number":["197785619\/SFB1021"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI109762"],"award-info":[{"award-number":["U19 AI109762"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106917\/Z\/15\/Z"],"award-info":[{"award-number":["106917\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Viruses"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ebolavirus disease (EVD) is caused by multiple species of orthoebolavirus. Monoclonal antibodies (mAbs) against the virus glycoprotein (GP) are the only class of therapeutic approved for treatment of EVD caused by\n                    <jats:italic>Orthoebolavirus zairense (<\/jats:italic>\n                    Ebola virus, EBOV). Therefore, mAbs targeting multiple orthoebolavirus species may represent the next generation of EVD therapeutics. Broadly reactive anti-GP mAbs were produced; among these, mAbs 11886 and 11883 were broadly neutralizing in vitro. A 3.0\u2009\u00c5 cryo-electron microscopy structure of EBOV GP bound to both mAbs shows that 11886 binds a novel epitope bridging the glycan cap (GC), 3\n                    <jats:sub>10<\/jats:sub>\n                    pocket and GP2 N-terminus, whereas 11883 binds the receptor binding region (RBR) and GC. In vitro, 11886 synergized with a range of mAbs with epitope specificities spanning the RBR\/GC, including 11883. Notably, 11886 increased the breadth of neutralization by partner mAbs against different orthoebolavirus species. These data provide a strategic route to design improved mAb-based next-generation EVD therapeutics.\n                  <\/jats:p>","DOI":"10.1038\/s44298-026-00192-7","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:59:15Z","timestamp":1778158755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A broadly-neutralizing antibody against Orthoebolavirus glycoprotein that potentiates the breadth and neutralization of other antibodies"],"prefix":"10.1038","volume":"4","author":[{"given":"Francesca R.","family":"Donnellan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamseedhar","family":"Rayaprolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramila","family":"Rijal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"O\u2019Dowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Parvate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Callaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hariharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly C. L.","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben Diaz","family":"Avalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Hastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Schimanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"M\u00fcller-Kr\u00e4uter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Strecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Balaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Halfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica Ollmann","family":"Saphire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lightwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain R.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"192_CR1","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1093\/infdis\/jiw207","volume":"214","author":"JG Breman","year":"2016","unstructured":"Breman, J. G. et al. Discovery and description of Ebola Zaire virus in 1976 and relevance to the West African epidemic during 2013\u20132016. J. Infect. Dis. 214, S93\u2013S101 (2016).","journal-title":"J. Infect. Dis."},{"key":"192_CR2","doi-asserted-by":"crossref","unstructured":"Formenty, P. et al. Human infection due to Ebola virus, subtype C\u00f4te d\u2019Ivoire clinical and biologic presentation. J. Infect. Dis. 179, S48-53 (1999).","DOI":"10.1086\/514285"},{"key":"192_CR3","doi-asserted-by":"publisher","first-page":"e1000212","DOI":"10.1371\/journal.ppat.1000212","volume":"4","author":"JS Towner","year":"2008","unstructured":"Towner, J. S. et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 4, e1000212 (2008).","journal-title":"PLoS Pathog."},{"key":"192_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1126\/science.1172705","volume":"325","author":"RW Barrette","year":"2009","unstructured":"Barrette, R. W. et al. Discovery of swine as a host for the Reston ebolavirus. Science 325, 204\u2013206 (2009).","journal-title":"Science"},{"key":"192_CR5","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41564-018-0227-2","volume":"3","author":"T Goldstein","year":"2018","unstructured":"Goldstein, T. et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nat. Microbiol. 3, 1084\u20131089 (2018).","journal-title":"Nat. Microbiol."},{"key":"192_CR6","unstructured":"World Health Organization. Organisation mondiale de la, S. Lessons learnt in expediting prequalification and registration of Ebola Zaire vaccine \u2013 Enseignements tir\u00e9s du processus acc\u00e9l\u00e9r\u00e9 de pr\u00e9qualificationet d\u2019homologation du vaccin contre le virus Ebola Za\u00efre. Wkly. Epidemiol. Record Relev\u00e9 \u00e9pid\u00e9miol. Hebd. 95, 369\u2013378 (2020)."},{"key":"192_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40265-021-01483-4","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee, A. Ansuvimab: first approval. Drugs 81, 595\u2013598 (2021).","journal-title":"Drugs"},{"key":"192_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. REGN-EB3: first approval. Drugs 81, 175\u2013178 (2021).","journal-title":"Drugs"},{"key":"192_CR9","unstructured":"Prevention, C. f. D. C. a. History of Ebola Disease Outbreaks, <https:\/\/www.cdc.gov\/vhf\/ebola\/history\/chronology.html> (2023)."},{"key":"192_CR10","doi-asserted-by":"publisher","unstructured":"Sprecher, A. et al. Perspectives on advancing countermeasures for filovirus disease: report from a multi-sector meeting. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiad354 (2023).","DOI":"10.1093\/infdis\/jiad354"},{"key":"192_CR11","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293\u20132303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"192_CR12","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.cell.2022.01.025","volume":"185","author":"SM Anthony","year":"2022","unstructured":"Anthony, S. M. & Hensley, L. E. Cocktail party: low-dose antibody combinations deliver pan-ebolavirus protection. Cell 185, 943\u2013945 (2022).","journal-title":"Cell"},{"key":"192_CR13","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.1073\/pnas.95.10.5762","volume":"95","author":"VE Volchkov","year":"1998","unstructured":"Volchkov, V. E., Feldmann, H., Volchkova, V. A. & Klenk, H. D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. USA 95, 5762\u20135767 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"192_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature07082","volume":"454","author":"JE Lee","year":"2008","unstructured":"Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177\u2013182 (2008).","journal-title":"Nature"},{"key":"192_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep46374","volume":"7","author":"DR Beniac","year":"2017","unstructured":"Beniac, D. R. & Booth, T. F. Structure of the Ebola virus glycoprotein spike within the virion envelope at 11\u2009\u00c5 resolution. Sci. Rep. 7, 46374 (2017).","journal-title":"Sci. Rep."},{"key":"192_CR16","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1110656","volume":"308","author":"K Chandran","year":"2005","unstructured":"Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P. & Cunningham, J. M. Endosomal proteolysis of the ebola virus glycoprotein is necessary for infection. Science 308, 1643\u20131645 (2005).","journal-title":"Science"},{"key":"192_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1128\/JVI.05708-11","volume":"86","author":"M Brecher","year":"2012","unstructured":"Brecher, M. et al. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J. Virol. 86, 364\u2013372 (2012).","journal-title":"J. Virol."},{"key":"192_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cell.2015.12.044","volume":"164","author":"H Wang","year":"2016","unstructured":"Wang, H. et al. Ebola viral glycoprotein bound to its endosomal receptor niemann-pick C1. Cell 164, 258\u2013268 (2016).","journal-title":"Cell"},{"key":"192_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101339","volume":"61","author":"P Rijal","year":"2023","unstructured":"Rijal, P. & Donnellan, F. R. A review of broadly protective monoclonal antibodies to treat Ebola virus disease. Curr. Opin. Virol. 61, 101339 (2023).","journal-title":"Curr. Opin. Virol."},{"key":"192_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/pathogens11030374","volume":"11","author":"X Yu","year":"2022","unstructured":"Yu, X. & Saphire, E. O. Development and structural analysis of antibody therapeutics for filoviruses. Pathogens 11, 374 (2022).","journal-title":"Pathogens"},{"key":"192_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.immuni.2020.01.001","volume":"52","author":"P Gilchuk","year":"2020","unstructured":"Gilchuk, P. et al. Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization. Immunity 52, 388\u2013403.e312 (2020).","journal-title":"Immunity"},{"key":"192_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.immuni.2018.06.018","volume":"49","author":"P Gilchuk","year":"2018","unstructured":"Gilchuk, P. et al. Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein. Immunity 49, 363\u2013374.e310 (2018).","journal-title":"Immunity"},{"key":"192_CR23","doi-asserted-by":"publisher","unstructured":"Brannan, J. M. et al. Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates. Nat. Commun. 10 https:\/\/doi.org\/10.1038\/s41467-018-08040-w (2019).","DOI":"10.1038\/s41467-018-08040-w"},{"key":"192_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","volume":"169","author":"AZ Wec","year":"2017","unstructured":"Wec, A. Z. et al. Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses. Cell 169, 878\u2013890.e815 (2017).","journal-title":"Cell"},{"key":"192_CR25","doi-asserted-by":"publisher","unstructured":"Banadyga, L. et al. Atypical Ebola virus disease in a nonhuman primate following monoclonal antibody treatment is associated with glycoprotein mutations within the fusion loop. mBio 12 https:\/\/doi.org\/10.1128\/mBio.01438-20 (2021).","DOI":"10.1128\/mBio.01438-20"},{"key":"192_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.chom.2023.01.002","volume":"31","author":"V Rayaprolu","year":"2023","unstructured":"Rayaprolu, V. et al. Structure of the inmazeb cocktail and resistance to Ebola virus escape. Cell Host Microbe 31, 260\u2013272.e267 (2023).","journal-title":"Cell Host Microbe"},{"key":"192_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.celrep.2017.03.049","volume":"19","author":"KA Howell","year":"2017","unstructured":"Howell, K. A. et al. Cooperativity enables non-neutralizing antibodies to neutralize ebolavirus. Cell Rep. 19, 413\u2013424 (2017).","journal-title":"Cell Rep."},{"key":"192_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41594-019-0191-4","volume":"26","author":"BR West","year":"2019","unstructured":"West, B. R. et al. Structural basis of broad ebolavirus neutralization by a human survivor antibody. Nat. Struct. Mol. Biol. 26, 204\u2013212 (2019).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"192_CR29","doi-asserted-by":"publisher","unstructured":"Xiao, J. H. et al. Characterization of influenza virus pseudotyped with ebolavirus glycoprotein. J Virol. 92 https:\/\/doi.org\/10.1128\/JVI.00941-17 (2018).","DOI":"10.1128\/JVI.00941-17"},{"key":"192_CR30","doi-asserted-by":"publisher","unstructured":"Bentley, E. M. et al. Cross-neutralisation of novel bombali virus by ebola virus antibodies and convalescent plasma using an optimised pseudotype-based neutralisation assay. Trop. Med. Infect. Dis. 6 https:\/\/doi.org\/10.3390\/tropicalmed6030155 (2021).","DOI":"10.3390\/tropicalmed6030155"},{"key":"192_CR31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2017.04.038","volume":"169","author":"X Zhao","year":"2017","unstructured":"Zhao, X. et al. Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability. Cell 169, 891\u2013904.e815 (2017).","journal-title":"Cell"},{"key":"192_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1128\/JVI.02172-15","volume":"90","author":"ZY Keck","year":"2016","unstructured":"Keck, Z. Y. et al. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J. Virol. 90, 279\u2013291 (2016).","journal-title":"J. Virol."},{"key":"192_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep06881","volume":"4","author":"J Audet","year":"2014","unstructured":"Audet, J. et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci. Rep. 4, 6881 (2014).","journal-title":"Sci. Rep."},{"key":"192_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.celrep.2019.03.020","volume":"27","author":"P Rijal","year":"2019","unstructured":"Rijal, P. et al. Therapeutic monoclonal antibodies for ebola virus infection derived from vaccinated humans. Cell Rep. 27, 172\u2013186 (2019).","journal-title":"Cell Rep."},{"key":"192_CR35","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.cell.2022.02.023","volume":"185","author":"JC Milligan","year":"2022","unstructured":"Milligan, J. C. et al. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell 185, 995\u20131007.e1018 (2022).","journal-title":"Cell"},{"key":"192_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/infdis\/jiy532","volume":"219","author":"JC Milligan","year":"2019","unstructured":"Milligan, J. C. et al. Structural characterization of pan-ebolavirus antibody 6D6 targeting the fusion peptide of the surface glycoprotein. J. Infect. Dis. 219, 415\u2013419 (2019).","journal-title":"J. Infect. Dis."},{"key":"192_CR37","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2015.01.041","volume":"160","author":"T Hashiguchi","year":"2015","unstructured":"Hashiguchi, T. et al. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 160, 904\u2013912 (2015).","journal-title":"Cell"},{"key":"192_CR38","doi-asserted-by":"publisher","first-page":"10982","DOI":"10.1128\/JVI.01490-15","volume":"89","author":"E Davidson","year":"2015","unstructured":"Davidson, E. et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J. Virol. 89, 10982\u201310992 (2015).","journal-title":"J. Virol."},{"key":"192_CR39","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.aad6117","volume":"351","author":"J Misasi","year":"2016","unstructured":"Misasi, J. et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351, 1343\u20131346 (2016).","journal-title":"Science"},{"key":"192_CR40","doi-asserted-by":"publisher","first-page":"e1002991","DOI":"10.1371\/journal.ppat.1002991","volume":"8","author":"AR Williams","year":"2012","unstructured":"Williams, A. R. et al. Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against Pfrh5 and other merozoite antigens. PLOS Pathog. 8, e1002991 (2012).","journal-title":"PLOS Pathog."},{"key":"192_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.chom.2018.12.004","volume":"25","author":"AZ Wec","year":"2019","unstructured":"Wec, A. Z. et al. Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection. Cell Host Microbe 25, 39\u201348.e35 (2019).","journal-title":"Cell Host Microbe"},{"key":"192_CR42","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1016\/j.cell.2021.09.035","volume":"184","author":"P Gilchuk","year":"2021","unstructured":"Gilchuk, P. et al. Pan-ebolavirus protective therapy by two multifunctional human antibodies. Cell 184, 5593\u20135607.e5518 (2021).","journal-title":"Cell"},{"key":"192_CR43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/1087057114564760","volume":"20","author":"S Tickle","year":"2015","unstructured":"Tickle, S. et al. A fully automated primary screening system for the discovery of therapeutic antibodies directly from B cells. J. Biomol. Screen. 20, 492\u2013497 (2015).","journal-title":"J. Biomol. Screen."},{"key":"192_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jim.2006.08.010","volume":"316","author":"DJ Lightwood","year":"2006","unstructured":"Lightwood, D. J. et al. Antibody generation through B cell panning on antigen followed by in situ culture and direct RT-PCR on cells harvested en masse from antigen-positive wells. J. Immunol. Methods 316, 133\u2013143 (2006).","journal-title":"J. Immunol. Methods"},{"key":"192_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4161\/mabs.27044","volume":"6","author":"AM Clargo","year":"2014","unstructured":"Clargo, A. M. et al. The rapid generation of recombinant functional monoclonal antibodies from individual, antigen-specific bone marrow-derived plasma cells isolated using a novel fluorescence-based method. mAbs 6, 143\u2013159 (2014).","journal-title":"mAbs"},{"key":"192_CR46","doi-asserted-by":"crossref","unstructured":"Barrett, J. R. et al. Analysis of the diverse antigenic landscape of the malaria invasion protein RH5 identifies a potent vaccine-induced human public antibody clonotype. Cell 187, 4964-4980.e21 (2023).","DOI":"10.1016\/j.cell.2024.06.015"},{"key":"192_CR47","doi-asserted-by":"publisher","first-page":"JVI.00941","DOI":"10.1128\/JVI.00941-17","volume":"92","author":"JH Xiao","year":"2018","unstructured":"Xiao, J. H. et al. Characterization of influenza virus pseudotyped with ebolavirus glycoprotein. J. Virol. 92, JVI.00941\u201300917 (2018).","journal-title":"J. Virol."},{"key":"192_CR48","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1089\/10430340252898984","volume":"13","author":"C Demaison","year":"2002","unstructured":"Demaison, C. et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene Ther. 13, 803\u2013813 (2002).","journal-title":"Hum. Gene Ther."},{"key":"192_CR49","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/infdis\/jiv565","volume":"213","author":"SD Dowall","year":"2016","unstructured":"Dowall, S. D. et al. Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat ebola virus infection. J. Infect. Dis. 213, 1124\u20131133 (2016).","journal-title":"J. Infect. Dis."},{"key":"192_CR50","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.vaccine.2016.11.083","volume":"35","author":"DE Wilkinson","year":"2017","unstructured":"Wilkinson, D. E. et al. Comparison of platform technologies for assaying antibody to Ebola virus. Vaccine 35, 1347\u20131352 (2017).","journal-title":"Vaccine"},{"key":"192_CR51","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1073\/pnas.0708057105","volume":"105","author":"P Halfmann","year":"2008","unstructured":"Halfmann, P. et al. Generation of biologically contained Ebola viruses. Proc. Natl. Acad. Sci. USA 105, 1129\u20131133 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"192_CR52","doi-asserted-by":"publisher","unstructured":"Williamson, L. E. et al. Early human B cell response to ebola virus in four U.S. survivors of infection. J. Virol. 93 https:\/\/doi.org\/10.1128\/jvi.01439-18 (2019).","DOI":"10.1128\/jvi.01439-18"},{"key":"192_CR53","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cell.2019.05.025","volume":"178","author":"DGW Alanine","year":"2019","unstructured":"Alanine, D. G. W. et al. Human antibodies that slow erythrocyte invasion potentiate malaria-neutralizing antibodies. Cell 178, 216\u2013228.e221 (2019).","journal-title":"Cell"},{"key":"192_CR54","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijpara.2016.12.001","volume":"47","author":"J Jin","year":"2017","unstructured":"Jin, J. et al. Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal \u2018C-tag. Int. J. Parasitol. 47, 435\u2013446 (2017).","journal-title":"Int. J. Parasitol."},{"key":"192_CR55","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. CryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"192_CR56","first-page":"245","volume":"10812","author":"T Bepler","year":"2018","unstructured":"Bepler, T. et al. Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. Res. Comput. Mol. Biol. 10812, 245\u2013247 (2018).","journal-title":"Res. Comput. Mol. Biol."},{"key":"192_CR57","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"192_CR58","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"192_CR59","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."}],"container-title":["npj Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00192-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00192-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00192-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:02:45Z","timestamp":1783987365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00192-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1038\/s44298-026-00192-7","relation":{},"ISSN":["2948-1767"],"issn-type":[{"value":"2948-1767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.J.L., V.O\u2019.D. are employees of UCB Pharma and DJL holds stock and\/or stock options in UCB Pharma. F.R.D., S.J.D., D.J.L., V.O\u2019.D., A.R.T., P.R., and L.S. are inventors on patent applications relating to anti-Orthoebolavirus GP antibodies referenced in this manuscript (GB1900732.7, Oxford University Innovation Limited and UCB Biopharma SPRL. Status: Not in force) (GB1917480.4, Oxford University Innovation Limited, Status: not in force). V.R., A.P., H.C., C.H., D.P., S.H., K.S., R.D.A., K.H., H.M.K., T.S., A.B., P.H., and E.O.S. declare no competing financial interests. All authors declare no other competing non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}